Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease
The findings of this cohort study indicate that in patients with gout and CKD stage 3, lowering serum urate level to less than 6 mg/dL vs 6 mg/dL or greater using ULT was not associated with an increased risk of severe or end-stage kidney disease. These findings support optimizing ULT to achieve target serum urate levels when treating patients with gout and impaired kidney function.
Authors
- Yuqing Zhang (ORCID: https://orcid.org/0000-0001-7638-0888)
- Chao Zeng (ORCID: https://orcid.org/0000-0003-4889-5731)
- Robert Terkeltaub (ORCID: https://orcid.org/0000-0001-5368-7473)
- Guanghua Lei (ORCID: https://orcid.org/0000-0003-2987-138X)
- Jie Wei (ORCID: https://orcid.org/0000-0003-3510-8241)
- Nicola Dalbeth (ORCID: https://orcid.org/0000-0003-4632-4476)
- Xiaoxiao Li (ORCID: https://orcid.org/0000-0003-1612-0691)
- Yilun Wang (ORCID: https://orcid.org/0000-0002-9468-4110)
Institutions
- Harvard University (US)
- Central South University (CN)
- University of Auckland (NZ)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1001/jamainternmed.2024.6212
- Citations
- 25
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 8.48